CMS Sets Transparency Requirements For COVID-19 Tests, Extends CJR

CMS’ fourth COVID-19 interim final rule doubles down on the agency’s push for price transparency from providers, threatening penalties if they don’t make the cash price of COVID-19 diagnostics publicly available, and also extends the fifth year of the hip-and-knee bundles demonstration for six more months. The CARES Act requires providers to publicize the cash prices for COVID-19 diagnostic tests, CMS notes -- though COVID-19 response laws also require comprehensive private health insurance plans to cover COVID-19 testing without cost...